




### What is Component Resolved Diagnostics (CRD)?

Current ImmunoCAP® specific IgE (sIgE) testing provides valuable information about a patient’s sensitization to an allergen(s). The level of sIgE to any given allergen(s) is an important consideration when evaluating a patient’s allergic status, because it has been demonstrated that the probability of symptoms will increase with increasing amounts of sIgE. Component resolved diagnostics (CRD),<sup>1,2</sup> using ImmunoCAP technology, further refines our understanding of sensitization by characterizing a person’s sensitization pattern at the molecular level.

Traditional sIgE testing methods utilize “allergens” that contain complex mixtures of allergenic components and their epitopes. ImmunoCAP CRD replaces these complex extract based mixtures with purified recombinant and native protein molecules. When used in conjunction with traditional sIgE testing, ImmunoCAP CRD provides sIgE information at the individual component level.



**Figure 1.** Complex mixtures of allergenic components in Traditional sIgE testing (a) vs. tests for Component Resolved Diagnostics (b).

### How will ImmunoCAP CRD help the Allergy Specialists?

Specialists may use ImmunoCAP CRD to:

- better characterize sensitization patterns
- better understand the clinical risk for reactions in a patient
- determine the likelihood of cross-reactivity between allergens
- select appropriate patients for specific immunotherapy and customize treatment
- monitor response to specific immunotherapy

## Where is PiRL located and what is the purpose of PiRL?

The CLIA certified Phadia Immunology Reference Laboratory (PiRL) is based in Portage, MI at the U.S. Headquarters of Phadia. The mission of PiRL is to provide new, innovative immunology tests for sIgE antibodies, to help advance the understanding of immunology among specialists, using the proven ImmunoCAP assay platform. PiRL will not compete with other laboratories. These innovative assays are not FDA cleared and will be conducted in a controlled, laboratory environment by licensed Medical Technologists. The reagents are not commercially available. Additional information about the value and clinical utility of Component Resolved Diagnostics is available by accessing [www.immunocapinvitrosight.com](http://www.immunocapinvitrosight.com)<sup>3</sup>.

PiRL Medical and Scientific leaders include:  
Henry Homburger, MD, Laboratory Director  
Robert Reinhardt, MD, Sr. Director Medical Affairs and Quality Management  
Staffan Ahlstedt, PhD, Medical and Scientific Advisor

## What tests are available?

ImmunoCAP sIgE allergen component packages make it possible to characterize a unique, component-specific, IgE antibody pattern for each patient.

ImmunoCAP testing is available for a variety of components. For example, component packages for peanut, wheat and egg are listed. Please contact your PiRL representative for a complete list of components available through the Phadia Immunology Reference Laboratory (PiRL).

Peanut ( <i>Arachis hypogaea</i> )	Wheat ( <i>Triticum spp.</i> )	Egg ( <i>Gallus spp.</i> )
rAra h 1 rAra h 2 rAra h 3 rAra h 8 PR-10 rAra h 9 LTP	rTri a 19 Omega-5 Gliadin	nGal d 1 Ovomucoid nGal d 2 Ovalbumin nGal d 3 Conalbumin

## When and how do I begin to order?

PiRL is able to process your order for component allergen packages today. Feel free to contact a PiRL representative or call 800.346.4364, option 1 for a Customer Service Representative and ask for the PiRL division. Shipping supplies and ordering information will be provided to you. PiRL tests are available on a fee for service basis with direct to patient or physician “credit card” billing options.

[www.PiRLlab.com](http://www.PiRLlab.com) will be the primary information source for information about PiRL.

Allergy specialists are now able to easily access ImmunoCAP CRD to characterize sensitization patterns in their patients.

## References

1. Valenta R, Lidholm J, Niederberger V, Hauke B, Kraft D, Gronlund H. The Recombinant Allergen-based Concept of Component Resolved Diagnostics and Immunotherapy (CRD and CRIT). *Clin Exp Allergy* 1999;29:896-904.
2. Heiss S, Mahler V, Steiner R, Spitzauer S, Schweiger C, Kraft D, Valenta R. Component Resolved Diagnostics (CRD) of Type 1 Allergy with Recombinant Grass and Tree Pollen Allergens by Skin Testing. *J Invest Dermatol* 1999;113:830-837.
3. [www.immunocapinvitrosight.com](http://www.immunocapinvitrosight.com), Allergens

**ImmunoCAP**<sup>®</sup>  
Specific IgE blood test

ImmunoCAP is a US registered trademark of Phadia AB  
©2009 Phadia US Inc., a subsidiary of Phadia AB

**Phadia**

Phadia US Inc  
4169 Commercial Avenue  
Portage, MI 49002  
800.346.4364  
398696.01